The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
John P. Veluchamy(Cancer Center Amsterdam), Jan Spanholtz(AIMM Therapeutics (Netherlands)), Tanja D. de Gruijl(Dutch Cancer Society), Henk M.W. Verheul(Erasmus MC Cancer Institute), Nina Kok(AIMM Therapeutics (Netherlands))
Cited by 197
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|582
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
|Nature reviews. Cancer|2007|502